Abbott has entered a global partnership focusing on the integration of its advanced FreeStyle Libre continuous glucose monitoring (CGM) technology with the Medtronic automated insulin delivery (AID) and smart insulin pen systems.

This collaboration is set to connect Abbott's CGM sensor with Medtronic's AID algorithms, allowing for automatic insulin adjustments to maintain glucose levels within the desired range.

The CGM sensor, which is being developed by Abbott to work exclusively with Medtronic devices, will be sold by the latter.

AID systems are beneficial for individuals with both type 1 and type 2 diabetes who require multiple daily injections of rapid-acting insulin.

This partnership is the latest in a series of collaborations by Abbott aimed at improving diabetes care and providing more choices for people to confidently manage their insulin administration.

Abbott's Libre single-analyte CGM technology is already integrated with other insulin delivery companies’ AID offerings.

Abbott's diabetes care business executive vice-president Jared Watkin said: “Libre technology has set the standard for accurate, accessible, easy-to-use and reliable continuous glucose monitoring.

“Connecting this CGM built for Medtronic's insulin delivery systems and algorithms makes it easier for people to spend less time thinking about their diabetes and more time living.”

While the financial terms and commercial availability timeline of the partnership remain undisclosed, Medtronic has also announced the US Food and Drug Administration (FDA) approval of its Simplera CGM.

As Medtronic's first disposable, all-in-one CGM, Simplera is half the size of previous models and offers a simplified insertion and wear experience without the need for overtape.

The platform, which includes the new form factor CGM and the Simplera Sync sensor, is designed for integration with Medtronic's Smart MDI system and the MiniMed 780G system.

The Simplera CGM and Simplera Sync sensor have already received CE Mark in Europe and were launched earlier this year.

Medtronic plans to initiate a limited market release in the US, starting with existing standalone CGM and InPen customers upon receiving FDA clearance.

The Simplera Sync sensor is currently under FDA review in a separate regulatory filing and is not yet approved for commercial use in the US.